https://www.appliedxl.com/news/hrs-7535-diabetic-kidney-disease-readout-nct06415214 Biopharma News en 2026-07-19T19:15:24.510Z HRS-7535 cut albuminuria 32% versus placebo in diabetic kidney disease trial https://www.appliedxl.com/news/sglt2-inhibitors-post-mi-meta-analysis Biopharma News en 2026-07-19T19:24:45.213Z SGLT2 inhibitors cut heart failure hospitalization after MI without diabetes https://www.appliedxl.com/news/tegoprazan-h-pylori-non-inferiority Biopharma News en 2026-07-19T19:44:50.146Z Tegoprazan dual therapy misses non-inferiority mark against bismuth quadruple therapy for H. pylori https://www.appliedxl.com/news/regenxbio-surabgene-lomparvovec-sura-vec-abbv-rgx-314-nct03066258 Biopharma News en 2026-07-19T09:05:49.913Z REGENXBIO's sura-vec holds vision gains through 5 years in a 42-patient wet AMD cohort https://www.appliedxl.com/news/romosozumab-osteogenesis-imperfecta-data Biopharma News en 2026-07-19T19:54:50.029Z Romosozumab lifts spinal bone density in osteogenesis imperfecta but not the hip https://www.appliedxl.com/news/perfusion-guided-fluid-resuscitation-acute-skin-failure Biopharma News en 2026-07-18T19:14:50.054Z Perfusion-guided fluid strategy cuts skin failure in elderly ICU patients https://www.appliedxl.com/news/novo-nordisk-denecimig-hemophilia-frontier4-nct05685238 Biopharma News en 2026-07-18T19:35:12.265Z Denecimig every-2-weeks dosing holds up in 26-week FRONTIER4 hemophilia A interim look https://www.appliedxl.com/news/ropeginterferon-polycythemia-vera-dosing Biopharma News en 2026-07-18T20:24:47.031Z Ropeginterferon analysis links faster dosing to quicker phlebotomy-free control in PV https://www.appliedxl.com/news/oliceridine-intubation-anesthesia-readout Biopharma News en 2026-07-17T22:44:46.794Z Oliceridine cut the remifentanil dose needed to blunt intubation response